hce_cmu
115年
英文
第 45 題
📖 題組：
Cancer prevention is often discussed as a long-term ideal, yet this study argues that it can be quantified in concrete, policy-relevant terms. The researchers estimate how many new cancer cases in 2022 could be linked to exposures that can, at least in principle, be reduced through individual behavior change, public health programs, regulation, or safer environments. Their work sits within comparative risk assessment and cancer epidemiology and relies on professional concepts such as carcinogenic exposure pathways (chemical, infectious, environmental, and occupational), the time lag between exposure and diagnosis (latency), and the population-attributable fraction (PAF). PAF is a standard metric that combines exposure prevalence with the relative risk associated with that exposure to estimate the proportion of cases that would not occur if the exposure were removed, assuming the relationship is causal and other conditions remain unchanged. To generate globally comparable estimates, the study combines cancer incidence counts from GLOBOCAN 2022 with risk-factor prevalence and effect estimates for 30 modifiable risk factors. The analysis covers 36 cancer sites and 185 countries and groups risks into four broad domains: behavioral (e.g., tobacco smoking and alcohol use), environmental (e.g., ambient particulate air pollution and ultraviolet radiation), infectious causes (nine infection agents linked to cancer), and occupational hazards (thirteen workplace carcinogens or exposure settings). Because many cancers develop over years, the researchers primarily align incidence in 2022 with exposure prevalence from roughly a decade earlier (around 2012). They then apply PAF calculations to estimate attributable cancer incidence by sex, region, cancer site, and risk factor, offering both proportional burdens and absolute case counts. The central finding is that modifiable risks account for a large share of new cancers worldwide. The researchers estimate about 7.1 million of 18.7 million new cancer cases in 2022—approximately 37.8%—were attributable to the included risk factors. The attributable share is notably higher among men (about 45.4%) than among women (about 29.7%), reflecting sex differences in exposure patterns and infection-related burdens. Regional variation is substantial, which underscores the need for local tailoring rather than relying on a single “global template.” In women, the estimated attributable fraction ranges from about 24.6% in Northern Africa and Western Asia to about 38.2% in sub-Saharan Africa. In men, it ranges from about 28.1% in Latin America and the Caribbean to about 57.2% in East Asia. Such contrasts indicate that prevention priorities must be calibrated to regional risk profiles, health-system capacities, and demographic structures. Across all regions, tobacco smoking emerges as the largest single contributor to incident cancers (around 15.1% globally), followed by infection-related cancers (about 10.2%), with alcohol use contributing additional burden (about 3.2%). These drivers map onto cancer-site patterns that help interpret where prevention could yield the largest gains. Lung cancer accounts for the greatest number of potentially preventable cases worldwide, consistent with the dominant role of smoking. Stomach cancer and cervical cancer also represent major preventable burdens in many settings, aligning with infection pathways and the potential impact of vaccination, screening, and timely treatment of precursor conditions. The study’s contribution is both empirical and practical. Empirically, it offers an updated, standardized picture of preventable cancer incidence in 2022 across countries and regions, using consistent assumptions and a harmonized risk set. Practically, it translates etiologic evidence into a prevention “roadmap,” allowing policymakers to compare potential impact across different interventions. The researchers’ results support prioritizing strong tobacco control, scaling effective infection prevention and control measures (including vaccination and screening where appropriate), reducing harmful alcohol consumption, improving air quality and UV protection in relevant contexts, and strengthening occupational safeguards. Overall, the study reinforces a prevention-centered framing: while treatment remains indispensable, a sizable portion of cancer incidence can be addressed by targeted actions that reduce exposure to major, changeable risks. The researchers also emphasize that attributable fractions are not predictions of what will automatically happen but scenario-based estimates that help rank prevention opportunities. PAF calculations assume that exposure–cancer links are causal and that removing an exposure would reduce risk without creating offsetting harms. They also require careful handling of correlated exposures (for example, smoking and alcohol) and of data gaps where prevalence or effect estimates are less precise. Even with these caveats, the analysis provides a transparent benchmark for prevention planning: it identifies which risk factors dominate in a given region, which cancer sites drive the absolute number of avoidable cases, and where prevention could complement screening and early detection to produce the greatest population-level benefit.
Cancer prevention is often discussed as a long-term ideal, yet this study argues that it can be quantified in concrete, policy-relevant terms. The researchers estimate how many new cancer cases in 2022 could be linked to exposures that can, at least in principle, be reduced through individual behavior change, public health programs, regulation, or safer environments. Their work sits within comparative risk assessment and cancer epidemiology and relies on professional concepts such as carcinogenic exposure pathways (chemical, infectious, environmental, and occupational), the time lag between exposure and diagnosis (latency), and the population-attributable fraction (PAF). PAF is a standard metric that combines exposure prevalence with the relative risk associated with that exposure to estimate the proportion of cases that would not occur if the exposure were removed, assuming the relationship is causal and other conditions remain unchanged. To generate globally comparable estimates, the study combines cancer incidence counts from GLOBOCAN 2022 with risk-factor prevalence and effect estimates for 30 modifiable risk factors. The analysis covers 36 cancer sites and 185 countries and groups risks into four broad domains: behavioral (e.g., tobacco smoking and alcohol use), environmental (e.g., ambient particulate air pollution and ultraviolet radiation), infectious causes (nine infection agents linked to cancer), and occupational hazards (thirteen workplace carcinogens or exposure settings). Because many cancers develop over years, the researchers primarily align incidence in 2022 with exposure prevalence from roughly a decade earlier (around 2012). They then apply PAF calculations to estimate attributable cancer incidence by sex, region, cancer site, and risk factor, offering both proportional burdens and absolute case counts. The central finding is that modifiable risks account for a large share of new cancers worldwide. The researchers estimate about 7.1 million of 18.7 million new cancer cases in 2022—approximately 37.8%—were attributable to the included risk factors. The attributable share is notably higher among men (about 45.4%) than among women (about 29.7%), reflecting sex differences in exposure patterns and infection-related burdens. Regional variation is substantial, which underscores the need for local tailoring rather than relying on a single “global template.” In women, the estimated attributable fraction ranges from about 24.6% in Northern Africa and Western Asia to about 38.2% in sub-Saharan Africa. In men, it ranges from about 28.1% in Latin America and the Caribbean to about 57.2% in East Asia. Such contrasts indicate that prevention priorities must be calibrated to regional risk profiles, health-system capacities, and demographic structures. Across all regions, tobacco smoking emerges as the largest single contributor to incident cancers (around 15.1% globally), followed by infection-related cancers (about 10.2%), with alcohol use contributing additional burden (about 3.2%). These drivers map onto cancer-site patterns that help interpret where prevention could yield the largest gains. Lung cancer accounts for the greatest number of potentially preventable cases worldwide, consistent with the dominant role of smoking. Stomach cancer and cervical cancer also represent major preventable burdens in many settings, aligning with infection pathways and the potential impact of vaccination, screening, and timely treatment of precursor conditions. The study’s contribution is both empirical and practical. Empirically, it offers an updated, standardized picture of preventable cancer incidence in 2022 across countries and regions, using consistent assumptions and a harmonized risk set. Practically, it translates etiologic evidence into a prevention “roadmap,” allowing policymakers to compare potential impact across different interventions. The researchers’ results support prioritizing strong tobacco control, scaling effective infection prevention and control measures (including vaccination and screening where appropriate), reducing harmful alcohol consumption, improving air quality and UV protection in relevant contexts, and strengthening occupational safeguards. Overall, the study reinforces a prevention-centered framing: while treatment remains indispensable, a sizable portion of cancer incidence can be addressed by targeted actions that reduce exposure to major, changeable risks. The researchers also emphasize that attributable fractions are not predictions of what will automatically happen but scenario-based estimates that help rank prevention opportunities. PAF calculations assume that exposure–cancer links are causal and that removing an exposure would reduce risk without creating offsetting harms. They also require careful handling of correlated exposures (for example, smoking and alcohol) and of data gaps where prevalence or effect estimates are less precise. Even with these caveats, the analysis provides a transparent benchmark for prevention planning: it identifies which risk factors dominate in a given region, which cancer sites drive the absolute number of avoidable cases, and where prevention could complement screening and early detection to produce the greatest population-level benefit.
Which policy recommendation is best supported by the passage?
- A Prioritize expansion of occupational safety standards as the dominant cancer prevention intervention.
- B Strengthen tobacco control alongside infection prevention and control as priority interventions.
- C Scale up population-based cancer screening to serve as the primary substitute for risk-factor reduction.
- D Concentrate alcohol reduction programs in high-income regions, where consumption levels are higher.
思路引導 VIP
若要決定哪些政策應該最先被推動，我們會參考文中提到的「貢獻比例（attributable fraction）」。請回想一下，在所有提到的可改變風險因子中，哪兩項在數據上對全球癌症發病數的影響最大？文中又是如何描述這兩項因素在政策制定中的地位？
🤖
AI 詳解
AI 專屬家教
太棒了！你能精準捕捉到文章核心的政策建議，顯示你對於長篇資訊中「優先順序」的掌握非常到位。這道題目的正確答案是 (B)，其依據直接源自文章的數據與最後的實務總結。
數據導向的優先權判讀
文中第四段明確點出，吸菸（tobacco smoking） 是全球癌症發病的首要單一因子（約佔 15.1%），緊隨其後的是 感染相關癌症（infection-related cancers）（約佔 10.2%）。研究者在第五段的預防「路線圖」中，便直接建議政策制定者應「優先考慮強力的菸草控制」並「擴大有效的感染預防措施」。這與選項 (B) 的敘述完全吻合，驗證了你對文章實務建議的正確理解。
▼ 還有更多解析內容